Skip to main content
Log in

Intravenous Immunoglobulin G Treatment in ABO Hemolytic Disease of the Newborn, is it Myth or Real?

  • Original Article
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

Abstract

Intravenous Immunoglobulin G (IVIG) therapy has been used as a component of the treatment of hemolytic disease of the newborn. There is still no consensus on its use in ABO hemolytic disease of the newborn routinely. The aim of this study is to determine whether administration of IVIG to newborns with ABO incompatibility is necessary. One hundred and seventeen patients with ABO hemolytic disease and positive Coombs test were enrolled into the study. The subjects were healthy except jaundice. Infants were divided into two groups: Group I (n = 71) received one dose of IVIG (1 g/kg) and LED phototherapy whereas Group II (n = 46) received only LED phototherapy. One patient received erythrocyte transfusion in Group I, no exchange transfusion was performed in both groups. Mean duration of phototherapy was 3.1 ± 1.3 days in Group I and 2.27 ± 0.7 days in Group II (p < 0.05). Mean duration of hospital stay was 5.34 ± 2.2 days in Group I and 3.53 ± 1.3 days in Group II (p < 0.05). Mean duration of phototherapy was 4.0 ± 1.5 days and 2.73 ± 1.1 days in double and single doses of IVIG respectively, and this was statistically significant (p < 0.05). IVIG therapy didn’t decrease neither phototherapy nor hospitalization duration in infants with ABO hemolytic disease. Meticulus follow-up of infants with ABO hemolytic disease and LED phototherapy decreases morbidity. IVIG failed to show preventing hemolysis in ABO hemolytic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zipursky A, Bowman JM (1993) Isoimmune hemolytic disease. In: Nathan OG, Oski FA (eds) Haematology of infancy and childhood, 4th edn. WB Saunders, Philadelphia, pp 66–69

    Google Scholar 

  2. Usha KK, Sulochana PV (1998) Detection of high risk pregnancies with relation to ABO hemolytic disease of the newborn. Indian J Pediatr 65:863–865

    Article  CAS  PubMed  Google Scholar 

  3. Maisels MJ, Kring E (1992) Risk of sepsis in newborns with severe hyperbilirubinemia. Pediatrics 90:741–743

    CAS  PubMed  Google Scholar 

  4. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia (2004) Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 114:297–316

    Article  Google Scholar 

  5. Urbaniak SJ (1979) ADCC (K cell) lysis of human erythrocytes sensitized with Rhesus alloantibodies. II. Investigation into mechanism of lysis. Br J Haematol 42:315–328

    Article  CAS  PubMed  Google Scholar 

  6. Glader B, Allen G (2005) Neonatal hemolysis. In: Alarcon P, Werner E (eds) Neonatal hematology, 1st edn. Cambridge University Press, Cambridge, p 133

    Google Scholar 

  7. Orzalesi M, Gloria F, Lucarelli P, Bottini E (1973) ABO system incompatibility:relationship between direct Coombs’ test positivity and neonatal jaundice. Pediatrics 51:288–289

    CAS  PubMed  Google Scholar 

  8. Yaseen H, Khalaf M, Rashid N, Darwich M (2005) Does prophylactic phototherapy prevent hyperbilirubinemia in neonates with ABO incompatibility and positive coombs test? J Perinatol 25:590–594

    Article  PubMed  Google Scholar 

  9. Ouwehand WH, Smith G, Ranasinghe E (2000) Management of severe alloimmune thrombocytopenia in the newborn. Arch Dis Child Fetal Neonatal Ed 82:F173–F175

    Article  CAS  PubMed  Google Scholar 

  10. Ohlsson A, Lacy JB (2010) Intravenous immunoglobulin for suspected or subsequently proven infection in neonates (Cochrane Review). The Cochrane Library, Oxford (Updated Software, issue 3)

  11. Gottstein R, Cooke RWI (2003) Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed 88:F6–F10

    Article  CAS  PubMed  Google Scholar 

  12. Alpay F, Sarıcı SU, Okutan V, Erdem G, Ozcan O, Gökcay E (1999) High-dose intravenous immunglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 88:216–219

    Article  CAS  PubMed  Google Scholar 

  13. Girish G, Chawla D, Agarwal R, Paul VK, Deorari AK (2008) Efficacy of two dose regimes of intravenous immunoglobulin in Rh hemolytic disease of newborn-a randomised controlled trial. Indian Pediatr 45:653–659

    CAS  PubMed  Google Scholar 

  14. Elalfy MS, Elbarbary NS, Abaza HW (2011) Early intravenous immunoglobulin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn-a prospective randomisd controlled trial. Eur J Pediatr 170:461–467

    Article  CAS  PubMed  Google Scholar 

  15. Smits-Wintjens VE, Walther FJ, Rath ME, Lindenburg IT, te Pas AB, Kramer CM et al (2011) Intravenous immunoglobulin in neonates with rhesus hemolytic disease: a randomised controlled trial. Pediatrics 127:680–686

    Article  PubMed  Google Scholar 

  16. Migdad AM, Abdelbasit OB, Shaheed MM, Seidahmed MZ, Abomelha AM, Arcala OP (2004) Intravenous immunoglobulin G (IVIG) therapy for significant hyperbilirubinemia in ABO hemolytic disease of the newborn. J Matern Fetal Neonatal Med 16:163–166

    Article  Google Scholar 

  17. Demirel G, Akar M, Celik IH, Erdeve OH, Uras N, Oguz SS et al (2011) Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates. Int J Hematol 93:700–703

    Article  CAS  PubMed  Google Scholar 

  18. Vreman HJ, Wong RJ, Stevenson DK, Route RK, Reader SD, Fejer MM et al (1998) Light-emitting diodes: a novel light source for phototherapy. Pediatr Res 44:804–809

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Serdar Beken.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Beken, S., Hirfanoglu, I., Turkyilmaz, C. et al. Intravenous Immunoglobulin G Treatment in ABO Hemolytic Disease of the Newborn, is it Myth or Real?. Indian J Hematol Blood Transfus 30, 12–15 (2014). https://doi.org/10.1007/s12288-012-0186-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-012-0186-3

Keywords

Navigation